<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE us-patent-application SYSTEM "us-patent-application-v43-2012-12-04.dtd" [ ]><us-patent-application lang="EN" dtd-version="v4.3 2012-12-04" file="US20140005058A1-20140102.XML" status="PRODUCTION" id="us-patent-application" country="US" date-produced="20131218" date-publ="20140102"><us-bibliographic-data-application lang="EN" country="US"><publication-reference><document-id><country>US</country><doc-number>20140005058</doc-number><kind>A1</kind><date>20140102</date></document-id></publication-reference><application-reference appl-type="utility"><document-id><country>US</country><doc-number>13930852</doc-number><date>20130628</date></document-id></application-reference><us-application-series-code>13</us-application-series-code><classifications-ipcr><classification-ipcr><ipc-version-indicator><date>20060101</date></ipc-version-indicator><classification-level>A</classification-level><section>C</section><class>12</class><subclass>Q</subclass><main-group>1</main-group><subgroup>68</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source></classification-ipcr></classifications-ipcr><classifications-cpc><main-cpc><classification-cpc><cpc-version-indicator><date>20130101</date></cpc-version-indicator><section>C</section><class>12</class><subclass>Q</subclass><main-group>1</main-group><subgroup>6886</subgroup><symbol-position>F</symbol-position><classification-value>I</classification-value><action-date><date>20140102</date></action-date><generating-office><country>US</country></generating-office><classification-status>B</classification-status><classification-data-source>H</classification-data-source><scheme-origination-code>C</scheme-origination-code></classification-cpc></main-cpc></classifications-cpc><classification-national><country>US</country><main-classification>506  7</main-classification></classification-national><invention-title id="d0e43">METHODS AND MATERIALS FOR THE DIAGNOSIS OF PROSTATE CANCERS</invention-title><us-related-documents><us-provisional-application><document-id><country>US</country><doc-number>61665849</doc-number><date>20120628</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>61691743</doc-number><date>20120821</date></document-id></us-provisional-application><us-provisional-application><document-id><country>US</country><doc-number>61709517</doc-number><date>20121004</date></document-id></us-provisional-application></us-related-documents><us-parties><us-applicants><us-applicant sequence="00" app-type="applicant" designation="us-only" applicant-authority-category="assignee"><addressbook><orgname>Caldera Health Ltd.</orgname><address><city>Auckland</city><country>NZ</country></address></addressbook><residence><country>NZ</country></residence></us-applicant></us-applicants><inventors><inventor sequence="00" designation="us-only"><addressbook><last-name>WATSON</last-name><first-name>James Douglas</first-name><address><city>Auckland</city><country>NZ</country></address></addressbook></inventor><inventor sequence="01" designation="us-only"><addressbook><last-name>ELTON</last-name><first-name>Clare</first-name><address><city>Auckland</city><country>NZ</country></address></addressbook></inventor><inventor sequence="02" designation="us-only"><addressbook><last-name>MUSGRAVE</last-name><first-name>David Rex</first-name><address><city>Hamilton</city><country>NZ</country></address></addressbook></inventor></inventors></us-parties><assignees><assignee><addressbook><orgname>Caldera Health Ltd.</orgname><role>03</role><address><city>Auckland</city><country>NZ</country></address></addressbook></assignee></assignees></us-bibliographic-data-application><abstract id="abstract"><p id="p-0001" num="0000">Methods for diagnosing the presence of a disorder, such as prostate cancer, in a subject are provided, such methods including detecting the relative frequency of expression of RNA biomarkers in a biological sample obtained from the subject using RNA-seq technology and comparing the relative levels of expression with predetermined threshold levels. Levels of expression of at least two of the RNA biomarkers that are above the predetermined threshold levels are indicative of the presence of prostate cancer in the subject.</p></abstract></us-patent-application>